StockMarketWire.com - Verona Pharma said top-line data from its Phase 2a trial of a treatment for cystic fibrosis demonstrated that single doses achieved statistically significant increases in average forced expiratory volume in patients.

The data provided a 'solid foundation' for further development of the treatment, called RPL554, the company said.


At 1:46pm: [LON:VRP] Verona Pharma PLC share price was +23.5p at 147.5p



Story provided by StockMarketWire.com